168 related articles for article (PubMed ID: 22669764)
1. Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.
Held JM; Britton DJ; Scott GK; Lee EL; Schilling B; Baldwin MA; Gibson BW; Benz CC
Mol Cancer Res; 2012 Aug; 10(8):1120-32. PubMed ID: 22669764
[TBL] [Abstract][Full Text] [Related]
2. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
[TBL] [Abstract][Full Text] [Related]
3. Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Lipfert L; Fisher JE; Wei N; Scafonas A; Su Q; Yudkovitz J; Chen F; Warrier S; Birzin ET; Kim S; Chen HY; Tan Q; Schmidt A; Dininno F; Rohrer SP; Hammond ML; Rodan GA; Freedman LP; Reszka AA
Mol Endocrinol; 2006 Mar; 20(3):516-33. PubMed ID: 16223974
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
Chen D; Washbrook E; Sarwar N; Bates GJ; Pace PE; Thirunuvakkarasu V; Taylor J; Epstein RJ; Fuller-Pace FV; Egly JM; Coombes RC; Ali S
Oncogene; 2002 Jul; 21(32):4921-31. PubMed ID: 12118371
[TBL] [Abstract][Full Text] [Related]
5. Interactions between MAP kinase and oestrogen receptor in human breast cancer.
McGlynn LM; Tovey S; Bartlett JM; Doughty J; Cooke TG; Edwards J
Eur J Cancer; 2013 Apr; 49(6):1176-86. PubMed ID: 23265704
[TBL] [Abstract][Full Text] [Related]
6. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
Harrod A; Fulton J; Nguyen VTM; Periyasamy M; Ramos-Garcia L; Lai CF; Metodieva G; de Giorgio A; Williams RL; Santos DB; Gomez PJ; Lin ML; Metodiev MV; Stebbing J; Castellano L; Magnani L; Coombes RC; Buluwela L; Ali S
Oncogene; 2017 Apr; 36(16):2286-2296. PubMed ID: 27748765
[TBL] [Abstract][Full Text] [Related]
7. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
Al-Dhaheri MH; Rowan BG
Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
[TBL] [Abstract][Full Text] [Related]
9. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression.
Weitsman GE; Li L; Skliris GP; Davie JR; Ung K; Niu Y; Curtis-Snell L; Tomes L; Watson PH; Murphy LC
Cancer Res; 2006 Oct; 66(20):10162-70. PubMed ID: 17047081
[TBL] [Abstract][Full Text] [Related]
12. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
Gao A; Sun T; Ma G; Cao J; Hu Q; Chen L; Wang Y; Wang Q; Sun J; Wu R; Wu Q; Zhou J; Liu L; Hu J; Dong JT; Zhu Z
Nat Commun; 2018 Oct; 9(1):4180. PubMed ID: 30301939
[TBL] [Abstract][Full Text] [Related]
13. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Kondo N; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2008 Sep; 15(3):755-63. PubMed ID: 18550720
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription.
Duplessis TT; Williams CC; Hill SM; Rowan BG
Endocrinology; 2011 Jun; 152(6):2517-26. PubMed ID: 21505052
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
Dutertre M; Smith CL
Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex.
Rogatsky I; Trowbridge JM; Garabedian MJ
J Biol Chem; 1999 Aug; 274(32):22296-302. PubMed ID: 10428798
[TBL] [Abstract][Full Text] [Related]
17. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
Weitsman GE; Weebadda W; Ung K; Murphy LC
Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity.
Thomas RS; Sarwar N; Phoenix F; Coombes RC; Ali S
J Mol Endocrinol; 2008 Apr; 40(4):173-84. PubMed ID: 18372406
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
